论文部分内容阅读
目的:观察健脾养胃方联合FOLFOX4方案治疗晚期胃癌的临床效果与安全性。方法:将68例晚期胃癌患者随机分为2组,对照组采用FOLFOX4方案治疗,观察组在对照组治疗方案的基础上给予健脾养胃方治疗,评估比较2组临床疗效、中医证候评分、生存质量及毒副反应。结果:总有效率观察组52.9%,高于对照组,差异有统计学意义(P<0.01);治疗第7天、第14天、第28天,观察组中医证候评分均低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组KPS评分高于对照组,EORTC生命质量测定量表(EORTC QLQ-C30)积分低于对照组,差异均有统计学意义(P<0.05);观察组胃肠道反应发生率32.4%、肝肾毒性发生率26.5%、骨髓抑制发生率29.4%,均低于对照组,差异均有统计学意义(P<0.01,P<0.05)。结论:晚期胃癌患者采用健脾养胃方联合FOLFOX4方案治疗,可缓解临床症状,控制发生毒副反应,提高生存质量。
Objective: To observe the clinical effect and safety of Jianpi Yangwei Decoction combined with FOLFOX4 regimen in the treatment of advanced gastric cancer. Methods: Sixty-eight patients with advanced gastric cancer were randomly divided into two groups. The control group was treated with FOLFOX4 regimen. The observation group was given Jianpi Yangwei Decoction on the basis of the control group. The clinical efficacy, TCM syndrome score , Quality of life and side effects. Results: The total effective rate in observation group was 52.9%, which was significantly higher than that in control group (P <0.01). On the 7th, 14th and 28th day after treatment, the TCM syndrome scores in the observation group were lower than those in the control group , The difference was statistically significant (P <0.05). After treatment, KPS score in observation group was higher than that in control group. The score of EORTC QLQ-C30 was lower than that in control group P <0.05). The incidence of gastrointestinal reaction in observation group was 32.4%, the incidence of hepatorenal toxicity was 26.5% and the incidence of bone marrow suppression was 29.4%, which were all lower than those in control group (P <0.01, P < 0.05). Conclusion: The treatment of patients with advanced gastric cancer treated with Jianpi Yangwei Decoction combined with FOLFOX4 regimen can relieve the clinical symptoms, control side effects and improve the quality of life.